1395145-15-9

Basic information

• Product Name: 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril
• Synonyms: 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril
• CAS NO: 1395145-15-9
• Molecular Weight: 474.522
• Mol File: 1395145-15-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril(1395145-15-9)
• EPA Substance Registry System: 2-(4-(8-(2-aminobenzo[d]oxazol-5-yl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitril(1395145-15-9)

Safety Data

• Hazardous Substances Data: 1395145-15-9(Hazardous Substances Data)

Upstream product

• 915019-53-3 2-(4-(8-bromo-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1224844-66-9 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine 
• 915019-52-2 2-[4-(3-amino-6-bromo-quinolin-4-ylamino)-phenyl]-2-methyl-propionitrile 
• 915019-51-1 2-(4-((6-bromo-3-nitroquinolin-4-yl)amino)phenyl)-2-methylpropanenitrile 
• 74189-16-5 2-amino-5-bromobenzoic acid hydrochloride 
• 723281-72-9 6-bromo-4-chloro-3-nitroquinoline 
• 853908-50-6 6-bromo-3-nitroquinolin-4-ol 
• 853908-49-3 5-bromo-2-((2-nitroethenyl)amino)benzoic acid 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 
• 115279-57-7 2-(4-aminophenyl)-2-methylpropionitrile 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.